Navigating Indonesia’s food supplement registration when your product is contract-manufactured abroad or contains an ingredient BPOM hasn’t seen before.
Contract Manufacturing, and the Problem BPOM Creates for Importers
Contract manufacturing (known locally as maklon, or globally as OEM) is the backbone of the supplement industry. A brand owner designs the formula, a third-party factory produces it, and the brand owner sells it under their own name. Straightforward. Except for BPOM. They don’t see it that way.
BPOM does have a box for OEM imports, but it is locked behind impossible protectionist requirements (proving local factories can’t make it). Therefore, the only viable strategy for foreign brand owners is to legally masquerade their OEM factory as a “Foreign Principal” via the Standard Import pathway, using a CFS and an LoA.
BPOM does formally recognize contract manufacturing, officially defining it as Suplemen Kesehatan Kontrak (Contract Health Supplements). When an Indonesian entity uses a foreign OEM, it falls under a highly specific registration pathway called Contract Manufacturing Abroad (Kontrak ke Luar Negeri).
| ⚠ THE CORE PROBLEM BPOM intentionally makes the “Contract Manufacturing Abroad” pathway nearly impossible for standard brand owners to use. To register a product through this specific OEM box, BPOM requires two strict conditions that most importers fail:The Registrant Restriction: A standard Indonesian trading company or distributor (PT) cannot apply for this. The Indonesian registrant must be a licensed Pharmaceutical Industry (Industri Farmasi) or a Traditional Medicine Industry (IOT).The Technology Barrier: You must formally prove with justification documents that the technology and facilities required to manufacture your supplement do not yet exist in Indonesia. |
In practice, the registrant (an Indonesian legal entity) must present a valid manufacturing certificate and Letter of Authorization (LoA) from the overseas factory. Without recognising OEM as a relationship type, BPOM interprets the factory as a passive supplier, raising questions about who is actually accountable for product quality. This is the friction point most importers hit.
Because most brand owners cannot prove a “lack of local technology,” they are forced to abandon the “Contract Manufacturing” pathway and squeeze their OEM arrangement into the Standard Import (Suplemen Kesehatan Impor) pathway, which triggers the aforementioned friction points.
“BPOM simply doesn’t have a box to put OEM products in. Your job is to fit the arrangement into a box it already recognises”
POSSIBLE WAY OUTS
| A | Letter of Authorization + Manufacturing Agreement (most common)The overseas manufacturer issues a formal LoA authorising a named Indonesian entity to register and commercialise the product in Indonesia. Pair this with a manufacturing agreement and a Certificate of Free Sale (CFS) from the country of origin. This is the cleanest path for most OEM arrangements; BPOM receives it as a brand-licensing relationship rather than a pure OEM play. |
| B | Register under a licensed local distributor or principalWhile partnering with a local distributor is the right move, BPOM will not treat your OEM factory as “their contracted manufacturer.” Because the local distributor is not in the pharmaceutical industry, they are legally barred from using the contract manufacturing route. BPOM will evaluate this exactly like Option A: a standard import where the foreign OEM is recognized as the Principal supplying a local distributor. |
| C | Negotiate brand co-ownership with the factoryIn some cases, the OEM factory agrees to be listed as the brand owner (or co-owner) for the Indonesian registration specifically, while commercial rights remain with you via a separate private agreement. This works when the factory relationship is strong and long-term, but it creates a legal dependency that must be structured carefully. This is the most practical workaround for the “CFS Catch-22.” Because BPOM requires a CFS for standard imports, the product must actually be legally registered and free to be sold in the OEM’s home country. Many OEMs manufacture exclusively for export and cannot get a CFS. Having the factory co-own or register the brand locally in their country to secure the government-issued CFS is a mandatory step before they can issue the LoA to your Indonesian distributor |
| 💡 PRACTICAL NOTE Whichever route you choose, ensure your overseas factory holds GMP certification recognised by BPOM (ISO 22000, HACCP, or a national GMP certificate). Without it, no amount of legal structuring will get the registration through. BPOM’s Directorate for Food Processed Products handles supplement imports, getting their pre-submission guidance informally can save months. |
When an Ingredient Isn’t on BPOM’s Approved List
BPOM maintains a positive list of permitted ingredients for food supplements under its regulations (Peraturan BPOM tentang Bahan Tambahan Pangan and related decrees). If your formula contains an ingredient outside this list, a novel botanical, a proprietary peptide, a cutting-edge micronutrient, the registration will stall or be outright rejected.
The instinct is to ask first. That instinct is correct. The question is how you ask.
CHANNELS TO REACH BPOM
| WA Quick, informal. Responses inconsistent, rarely binding. | @ Email / Letter Creates paper trail. Can take weeks; often formulaic. | ✓ Direct Visit Face-to-face with the directorate. Best for complex cases. RECOMMENDED |
WhatsApp and email have their place for routine clarifications, but for an ingredient that isn’t on the positive list, a direct visit to BPOM’s office, specifically the Direktorat Standardisasi Pangan Olahan, is where the real conversation happens. Officers can engage substantively with your dossier, ask follow-up questions in real time, and give informal signals about the likelihood of approval that a written response never would.
WHAT TO PREPARE BEFORE THE VISIT
- Comparable products already on the Indonesian market. Find registered supplements that contain structurally similar or functionally equivalent ingredients. Bring physical samples or printouts of their BPOM registration numbers (Nomor Izin Edar). This shows BPOM that the safety profile is not unprecedented.
- International regulatory approvals. GRAS (Generally Recognized As Safe) status from the US FDA, EU Novel Food authorisation, TGA listing in Australia, or Singapore HSA approval are powerful reference points. BPOM looks favourably on ingredients validated by peer regulators.
- Safety and efficacy dossier. Compile peer-reviewed literature, toxicology data, and clinical study summaries. The dossier doesn’t need to be exhaustive at this stage, you’re in a pre-submission conversation, but it must demonstrate that you have done the scientific homework.
- Proposed specification and use level. Come with a clear proposed usage level (e.g. mg per serving), a technical specification for the ingredient, and the intended health function. Vague requests get vague answers.
- Your contact and company credentials. Bring your company’s and the draft product concept. Even at a pre-submission stage, BPOM officers respond better to representatives who look prepared and commercially credible.
| ℹ STRATEGIC TIP If BPOM signals that the ingredient is unlikely to be approved, ask about the formal scientific assessment process (kajian ilmiah), BPOM can evaluate new ingredients for potential inclusion in the positive list, though the timeline is long (often 1–2 years). Alternatively, consider whether a structurally related, approved ingredient could achieve the same functional outcome at the formula level. Reformulation is not defeat, it is often the fastest path to market. |
Expect that a single visit will rarely resolve the matter. BPOM’s process is iterative. Plan for at least two to three interactions: an initial discussion, a follow-up with supplementary documentation, and a final pre-submission meeting. Building rapport with the relevant directorate officer over those visits is itself a strategic asset.
